Skip to main content
. 2021 May-Jun;37(3):805–811. doi: 10.12669/pjms.37.3.3552

Table II.

Antigen expression in B-ALL (n=855), T-ALL (n=209) and Non APL AML (n=261, excluding AML-not otherwise classified).

Antigens Expression, n/N (%)

B-ALL T-ALL Non APL AML
CD 45 669/771(86.8) 185/186(99) 78/79(98.7)
TdT 802/843(95) 171/206(83) 24/98(24.5)
CD34 519/833(62.3) 51/200(25.5) 68/123(55.3)
CD117 3/150(2) 3/91(3.3) 74/109(67.8)
CD79a 814/815(99.8) 20/180(11.1) 6/90(6.6)
CD 19 769/776(99) 0/187 5/90(5.5)
CD22 590/642(92) 2/166(1.2) 3/73(4.1)
CD20 434/731(59.4) 0/161 0/65
CD10 792/836(94.7) 95/177(53.6) 2/63(3.2)
CD3 0/829 209/209(100) 0/114
CD5 - 166/184(90.2) 23/50(46)
CD4 3/163(1.8) 162/204(79.4) 23/50(46)
CD8 - 109/203(53.7) 0/24
CD7 - 22/24(91.7) -
CD4/8 co-expression - 102/203(50.2) -
CD4/8 double negative - 35/203(17.2) -
CD4pos/CD8neg - 59/172(34.3) -
CD8pos/CD4neg - 7/203(3.4) -
MPO (Cyto/IHC/FC) 0/685 0/196 202/261(77.4)
CD13 194/651(29.8) 13/161(8.1) 91/106(85.8)
CD33 122/708(17.2) 13/173(7.5) 97/106(91.5)
CD15 101/496(20.3) 9/109(8.3) 44/70(62.8)
HLADR 179/183(97.8) 15/61(24.6) 41/62(66.1)
CD64 - - 33/90(36.7)
CD36 - - 10/54(18.5)
CD11C - - 15/41(36.5)
cyCD61 - - 9/88(10.2)
GlyA - - 2/72(2.7)
CD66 191/619(30.8) 0/142 10/56(17.8)
CD58 332/343(96.8) 80/99(80.8) 33/38(86.8)
CD9 393/410(95.8) 33/100(33) 24/43(55.8)

CD: Cluster of differentiation, Cyto: Cytochemistry, FC: Flowcytometry, HLA DR: Human leukocyte antigen, IHC: Immunohistochemisty, MPO: Myeloperoxidase, n/N: No. of antigen postive/ Total no. of cases tested, TdT: Terminal deoxynucleotidyltransferase, GlyA: Glycophorin A